MacroGenics is a biopharmaceutical company developing antibody-based therapeutics for cancer, leveraging proprietary platforms including antibody-drug conjugates (ADCs) and multi-specific antibodies (DART and TRIDENT molecules) to create product candidates targeting solid tumors and hematologic malignancies. The company generates revenue through both product licensing and royalties on marketed therapies and through contract development and manufacturing services provided to pharmaceutical partners, with commercial-scale cGMP manufacturing capabilities supporting both its own clinical programs and outsourced services. Strategic collaborations with companies such as Gilead Sciences and royalty agreements provide substantial non-dilutive funding that helps offset operating costs while the company advances its clinical pipeline and early-stage programs.